Clinical Trial Update: Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing denosumab to zoledronic acid for bone metastases in men with hormone-refractory prostate cancer completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Prostate Cancer

Drugs mentioned

• Denosumab (denosumab)
• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Amgen | Conditions: Bone Metastases | Phase 3 | Status: COMPLETED | Results posted: 2014-03-21